Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Get Free Report) hit a new 52-week low on Tuesday . The company traded as low as $27.84 and last traded at $28.09, with a volume of 59143 shares. The stock had previously closed at $28.44.
Analysts Set New Price Targets
A number of brokerages recently weighed in on COLL. Needham & Company LLC raised Collegium Pharmaceutical from a "hold" rating to a "buy" rating and set a $46.00 price objective on the stock in a report on Friday, January 10th. Piper Sandler dropped their price objective on Collegium Pharmaceutical from $37.00 to $36.00 and set a "neutral" rating on the stock in a report on Tuesday, February 4th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $50.00 price objective on shares of Collegium Pharmaceutical in a report on Friday, January 10th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, Collegium Pharmaceutical has an average rating of "Moderate Buy" and a consensus price target of $43.60.
Read Our Latest Analysis on Collegium Pharmaceutical
Collegium Pharmaceutical Price Performance
The company has a quick ratio of 0.88, a current ratio of 0.97 and a debt-to-equity ratio of 3.43. The company has a market cap of $910.26 million, a price-to-earnings ratio of 12.46 and a beta of 0.99. The company has a fifty day simple moving average of $30.78 and a two-hundred day simple moving average of $33.23.
Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last posted its earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share for the quarter, beating the consensus estimate of $1.54 by $0.09. The company had revenue of $181.95 million for the quarter, compared to analyst estimates of $179.68 million. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. On average, equities research analysts anticipate that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current fiscal year.
Insider Buying and Selling at Collegium Pharmaceutical
In other news, EVP Shirley R. Kuhlmann sold 26,067 shares of the company's stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $28.50, for a total value of $742,909.50. Following the sale, the executive vice president now directly owns 108,137 shares in the company, valued at $3,081,904.50. This represents a 19.42 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last 90 days, insiders have sold 93,567 shares of company stock valued at $2,774,710. Insiders own 3.98% of the company's stock.
Institutional Trading of Collegium Pharmaceutical
Several institutional investors and hedge funds have recently made changes to their positions in the stock. Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in shares of Collegium Pharmaceutical in the fourth quarter valued at $3,489,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of Collegium Pharmaceutical by 11.9% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 66,389 shares of the specialty pharmaceutical company's stock valued at $1,902,000 after acquiring an additional 7,063 shares in the last quarter. Velan Capital Investment Management LP purchased a new stake in shares of Collegium Pharmaceutical in the fourth quarter valued at $822,000. Vident Advisory LLC lifted its position in shares of Collegium Pharmaceutical by 27.8% in the fourth quarter. Vident Advisory LLC now owns 16,898 shares of the specialty pharmaceutical company's stock valued at $484,000 after acquiring an additional 3,672 shares in the last quarter. Finally, Virtus Fund Advisers LLC lifted its position in shares of Collegium Pharmaceutical by 30.5% in the fourth quarter. Virtus Fund Advisers LLC now owns 2,419 shares of the specialty pharmaceutical company's stock valued at $69,000 after acquiring an additional 565 shares in the last quarter.
About Collegium Pharmaceutical
(
Get Free Report)
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.
Featured Articles
Before you consider Collegium Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Collegium Pharmaceutical wasn't on the list.
While Collegium Pharmaceutical currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
